Issue of Equity

12 September 2016

Collagen Solutions Plc

(the "Company" or "Collagen Solutions")

Issue of Equity and Director/PDMR Shareholding

Issue of Equity

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces that it has issued, in aggregate, 8,217,475 new ordinary shares in the Company ("Ordinary Shares") to certain vendors in order to satisfy the initial tranche of the deferred consideration share provisions in relation to the Collbio Limited ("Collbio") acquisition, as announced on 10 December 2013, and the ChondroMimetic assets acquisition, as announced on 14 September 2015.

Application has been made for the 8,217,475 new Ordinary Shares to be admitted to trading on AIM ("Admission"), which is expected to occur at 8.00 a.m. on or around 13 September 2016. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares. Following Admission, and for the purposes of the Disclosure and Transparency Rules, the Company's total issued share capital will consist of 179,621,290 Ordinary Shares. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company.

Director/PDMR Shareholding

The Company announces that, pursuant to the issue of Ordinary Shares in respect of the satisfaction of the initial tranche of deferred consideration for the Collbio acquisition, Mr David Evans, Chairman of the Company and a vendor of Collbio, was issued 2,685,437 new Ordinary Shares at a strike price of 12.5p per Ordinary Share, and Dr Stewart White, Chief Scientific Officer and a vendor of Collbio, was issued 1,553,592 Ordinary Shares at a strike price of 12.5p per Ordinary Share. Following the issue of new Ordinary Shares to Mr Evans and Dr White, Mr Evans' total beneficial holding in the Company has increased to 18,874,167 Ordinary Shares, representing 10.5 per cent. of the issued ordinary share capital of the Company following Admission, and Dr White's total beneficial holding in the Company has increased to 5,017,919 Ordinary Shares, representing 2.8 per cent. of the issued ordinary share capital of the Company following Admission respectively.

Enquiries: